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Background: Lewy body disorders (LBD) are clinical syndromes characterized
by pathological inclusions containing α-synuclein. Cognitive deficits are common or
diagnostic in LBD, and may be associated with the presence of beta-amyloid (Aβ), which
is a hallmark histopathologic abnormality characteristic of Alzheimer’s disease (AD) that
can also co-occur with LBD.
Objective: In the present study we evaluated whether social decision-making difficulties
in LBD are associated with Aβ burden.
Methods: Decision-making abilities were measured with a simple, untimed, behavioral
task previously validated in patients with behavioral variant frontotemporal dementia, and
performance was related to gray matter atrophy on MRI. Aβ burden was assessed by
examination of cerebrospinal fluid (CSF) level of Aβ1−42 and by autopsy confirmation in
a subgroup of patients.
Results: The results revealed that LBD patients with evidence of Aβ have reduced social
decision-making abilities compared to patients with no evidence of Aβ. The imaging
analysis related greater decision-making difficulty in Aβ-positive patients in respect to
Aβ-negative patients to gray matter atrophy in medial orbitofrontal. This region is a
critical node of a decision-making network as well as a region previously associated
with comorbid α-synuclein and Aβ in LBD.
Conclusions: These preliminary findings suggest that cognitive difficulties in LBD extend
to include deficits in social decision-making and that this may be related to the presence
of Aβ.
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INTRODUCTION
Lewy body disorders (LBD) encompass a range of
neurodegenerative clinical conditions including Parkinson’s
disease (PD), Parkinson’s disease dementia (PDD) and dementia
with Lewy bodies (DLB) that share a common pathological
substrate. Specifically, LBD is characterized by pathological
inclusions containing the synaptic protein α-synuclein (α-syn)
in the cell bodies and processes of surviving neurons (known
as Lewy bodies and Lewy neurites, respectively; Goedert et al.,
2012; Irwin et al., 2013). Cognitive deficits are common in LBD.
Roughly 80% of PD patients eventually evolve over several
years to PDD (Emre et al., 2007; Halliday et al., 2008) and, as
cognitive deficits are emerging, PD patients can meet criteria
for mild cognitive impairment (PD-MCI; Litvan et al., 2012). In
other patients, the time between the onset of Parkinsonism and
dementia is observed to be within 1 year, or dementia may be
present prior to the onset of motor features. These patients are
diagnosed with dementia with Lewy bodies (DLB; McKeith et al.,
2005; McKeith, 2006; Lippa et al., 2007). Autopsy studies of DLB
patients often show that α-syn is not the only histopathologic
abnormality that is observed, with several studies also observing
co-occurring histopathologic features of Alzheimer’s disease
(AD). This includes the presence of beta-amyloid (Aβ) plaques
and neurofibrillary tangles composed of tau (Kotzbauer et al.,
2012). While Aβ is often associated with DLB (Lippa et al.,
2007), there is also considerable evidence that Aβ is found in a
significant percentage of patients with PDD (Hurtig et al., 2000;
Irwin et al., 2013) and recent evidence suggests that over 15% of
de novo PD patients have evidence of Aβ (McMillan and Wolk,
2016).
The range of cognitive deficits observed in LBD includes
deficits in visuoconstructional, episodic memory, and language
domains. Executive deficits are arguably the most common
cognitive impairment observed in the LBD spectrum (Levin et al.,
1991; Rosenthal et al., 2010; Dirnberger and Jahanshahi, 2013).
This is closely aligned with difficulties in decision-making and
social functioning (Bodden et al., 2010; Djamshidian et al., 2014),
and these deficits can have a profound impact on patients’ daily
lives (Lo et al., 2009; Rosenthal et al., 2010).
With the emergence of potential disease-modifying
treatments, there is considerable interest in defining more
specifically the neurobiologic basis for cognitive difficulties, and
developing inexpensive, non-invasive screening tools that can
both help improve pathology-associated diagnosis and serve as
a validated, repeatable endpoint in an intervention study. One
potential strategy would involve associating specific cognitive
difficulties with a particular histopathologic abnormality. For
instance, elevated amyloid retention on PET imaging appears
to be associated with cognitive deficits in patients with DLB
(Gomperts et al., 2012), PD-MCI (Petrou et al., 2012) and also
in non-demented PD patients (Gomperts et al., 2013). However,
some studies (Jokinen et al., 2010) found no association between
amyloid PET uptake and cognitive functioning in LBD. There
is a close relationship between CSF and PET imaging measures
of amyloid (Landau et al., 2013; Palmqvist et al., 2015), and a
related strategy demonstrates an association between cognitive
difficulty and the cerebrospinal fluid (CSF) level of Aβ1−42
(Alves et al., 2010; McMillan and Wolk, 2016). In particular CSF
Aβ1−42 in early PD has been associated with increased frontal
lobe dysfunctions including executive impairments relative to
individuals with early PD and no evidence of Aβ pathology
(McMillan and Wolk, 2016). Given the inconsistent results in
these approaches, it would be valuable to have independent
validation of the association between cognitive difficulty and
amyloid in LBD that might come in part from relating amyloid
to a specific anatomic locus of a cognitive deficit.
In the present study, we sought to provide preliminary
evidence of the impact of amyloid pathology on a measure of
social decision-making, which involves prefrontal networks, in
patients with LBD.
The task we employed was developed to investigate decision-
making during social coordination. Social decisions often require
two individuals to converge on the same thought despite the
absence of explicit information. In game-theoretic terms, this
ability of getting on the same page’ without a direct exchange
of information is called a “coordination game.” In certain
coordination games, players can only reach the solution by
inferring implicit mutual knowledge between the participants. In
other words, players must use a “focal point,” defined as a salient
source of information known to both players, which transcends
the mathematical structure of the game (Schelling, 1969). In a
seminal study, Mehta et al. (1994) asked participants to select a
boy’s name under two conditions: “picking” (pick any name) and
“coordination” (pick the same name as a random partner). The
name “John” was only given in 9% of “picking” responses but
was given in 50% of “coordination” responses. Thus, due to the
belief that a random partner would have in mind a name that
many believe is common, participants in this study established
the common name “John” as a focal point. Notably, this paradigm
is simple, untimed, requires a minimal response of one word, yet
involves an essential decision-making process that we use all the
time.
Previous work from our group has employed a modified
version of Mehta et al. paradigm to investigate decision-
making abilities during social coordination in patients affected
by behavioral variant frontotemporal degeneration (bvFTD)
(McMillan et al., 2012). This is a neurodegenerative condition
that compromises prefrontal functioning with minimal impact
on language (Rascovsky et al., 2011). This work showed that
bvFTD patients are impaired in establishing a focal point, and
associated these difficulties with cortical thinning in a network
of prefrontal regions including ventromedial, ventrolateral, and
dorsolateral prefrontal cortex as well as medial orbitofrontal
cortex. These prefrontal areas were also previously associated
with Aβ in LBD patients (McMillan and Wolk, 2016).
Patients were divided into Aβ-positive and Aβ-negative
groups on the basis of a validated CSF Aβ1−42 level (Shaw et al.,
2009) or autopsy confirmed amyloidosis (McKeith, 2006). A
subgroup of participants also had high-resolution MRI scans to
correlate behavioral performance with regional decrease in gray
matter (GM) density. We hypothesized that decision-making
difficulties in LBD patients would be more pronounced in
individuals with a significant Aβ burden, and that this would be
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associated with a reduction in GM density in prefrontal regions
contributing to decision-making.
MATERIALS AND METHODS
Participants
From a cohort of 77 patients with a LBD disorder evaluated with
this decision-making paradigm, we selected 37 patients with a
clinical diagnosis of a LBD disorder who also underwent the
CSF protocol (N = 32) or for which autopsy examination
was available (N = 5). This group included 8 patients with
PD, 15 patients with PD-MCI, 6 patients with PDD, and 8
patients with DLB. Patients were diagnosed by neurologists
using published consensus criteria (Hughes et al., 1992; McKeith,
2006; Emre et al., 2007; Litvan et al., 2012). Patients with
other neurodegenerative diseases were excluded. Patients with
a neurologic condition such as stroke or hydrocephalus, a
primary psychiatric disorder, or a medical condition causing
cognitive difficulty were also excluded. We also assessed a
group of 30 community-dwelling healthy seniors (see Table 1
for participants’ demographic information and statistics). All
subjects participated in an informed consent procedure approved
by the University of Pennsylvania Institutional Review Board.
Behavioral Procedure and Analysis
Participants were presented with 10 questions (e.g., “Tell me
the name of any _____”) probing a familiar semantic category
(e.g., “fabric,” “boy’s name,” “supermarket item”), as described
previously (McMillan et al., 2012). In the Survey condition,
participants were told that we were conducting a survey and that
they could answer each question however they wished, allowing
us to obtain baseline performance. They were also informed that
the survey would not be followed by any memory test. Following
a 25-min delay during which other cognitive measures were
administered, each question was repeated in the Coordination
condition. Here, participants were instructed to provide the
answer that they thought another participant in the same survey
would have provided. Participants were always presented the
Survey condition first and then the Coordination condition, in an
effort to obscure the decision-making nature of the task.
Responses were quantified in both the Survey and
Coordination condition using a “Coordination Index” based on
the frequency of occurrence of each response provided during
the Coordination condition in the pool of healthy seniors. To
every response that was not provided by the group of healthy
seniors in the Coordination condition was given a frequency of
zero. For example, the pair of answers (survey and coordination
condition) “horse—chicken” in the category animals obtained
the scores: 0–1, while the pair “horse—cat” obtained the score:
0–8 (see McMillan et al., 2012 for further details). The scores of
the single categories were averaged in order to obtain two global
scores for each participant: one for the Survey condition and one
for the Coordination condition.
CSF Analysis
CSF samples were obtained by lumbar puncture using a 22-
gauge spinal needle as described in the Alzheimer’s Disease
TABLE 1 | Mean (±SEM) demographic data for the patients and the
healthy seniors groups (A), Mean (±SEM) demographic data for
amyloid-negative and amyloid-positive groups (B).
Demographic/clinical
measure
Patients (N = 37) Healthy seniors
(N = 30)
(A)
Age (years)* 70 (1) 65 (1)
Education (years) 15.8 (0.4) 14.9 (0.4)
Gender (female/male) 12/25 9/21
Ethnicity (Cw/BA/M)*1 36/1/0 22/7/1
MMSE score (max = 30)* 26.5 (0.7) 29.1 (0.1)
Disease duration (years) 10 (1) –
Test–CSF collection interval
(years)2
2.1 (0.3) –
Test–death interval (years)3 2.6 (0.2) –
Demographic/clinical
measure
Amyloid-negative
(N = 25)
Amyloid-positive
(N = 12)
(B)
Age (years) 69 (1) 70 (3)
Education (years)* 16.8 (0.5) 14.1 (0.7)
Gender (female/male) 8/17 4/8
MMSE score (max = 30)* 27.4 (0.6) 24.6 (1.6)
Disease duration (years) 11 (1) 7 (1)
Number PD cases 7 1
Number PD-MCI cases 11 4
Number PDD cases 4 2
Number DLB 3 5
CSF-date to behavioral test
(months)
27 (4) 20 (5)
*Significant difference between two groups. 1Cw, Caucasian-white; BA, Black-American;
M, mixed heritage. 2The data refers to the group of 32 patients for which a CSF
sample was available. 3The data refers to the group of 5 patients with neuropathological
examination.
(A) Patients and healthy seniors differed in age (Wilcoxon W = 359; p < 0.05), MMSE
score (Wilcoxon W = 809; p < 0.01) and ethnicity (comparison between Caucasian-
White American and Black-Americans: X2 = 5.1447; p < 0.05) while the two groups did
not differ in genders distribution (X2 < 0.0001; p > 0.9), and level of education (Wilcoxon
W = 440.5; p > 0.1). (B) Amyloid-negative and amyloid-positive patients did not differed
in age (Wilcoxon W = 136.5 p > 0.6), in gender distribution (X2 < 0.0001; p > 0.9) and in
the disease duration (WilcoxonW= 183; p> 0.1) while the two groups differed in the level
of education (Wilcoxon W = 234; p < 0.01) and in their MMSE score (Wilcoxon W = 788;
p < 0.05).
Neuroimaging Initiative (ADNI) procedures manual (http://
www.adni-info.org/). CSF was divided into aliquots (0.25mL)
and stored in bar code–labeled polypropylene vials at -80◦C.
Aβ1−42 was measured using the multiplex xMAP Luminex
platform (Luminex Corp, Austin, TX) with Innogenetics (INNO-
BIA AlzBio3; Ghent, Belgium; for research use only reagents)
immunoassay kit–based reagents (Shaw et al., 2009). Full details
for the combination of immunoassay reagents and analytical
platform employed in the present study are explained elsewhere
(Irwin et al., 2012). Reliability studies (http://www.adni-info.
org) show that the reproducibility for this biomarker varies by
<10%. In line with previous studies (Shaw et al., 2009), CSF
Aβ1−42 was analyzed as a binary measure employing a level
of ≤192 pg/mL as a cutoff (hereafter, amyloid-positive ≤192
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pg/mL; amyloid-negative≥192 pg/mL). This criterion allowed us
to identify two subgroups of patients: amyloid-positive patients
(≤192 pg/mL, n = 12) and amyloid-negative patients (≥192
pg/mL, n = 25).
Autopsy Procedure
A subset of PD spectrum patients had ante mortem MRI and
cognitive evaluations with autopsy confirmation of amyloidosis
(n = 5), and thus these patients were included for study. Briefly,
fresh tissue was dissected at autopsy, fixed, processed, and stained
according to standard procedures described elsewhere (Toledo
et al., 2011). A neuropathological diagnosis was performed
by an expert neuropathologist (EBL, JQT) using standard
criteria (McKeith et al., 2005; Montine et al., 2012). Cases
were classified into amyloid-positive and amyloid-negative groups
based evidences of comorbid Alzheimer’s disease: none or low
probability (amyloid-negative), intermediate or high probability
(amyloid-positive). Table 2 shows neuropathological group data.
Imaging Procedure and Analysis
High-resolution volumetric T1-weighted MRI was obtained
within 9 months of behavioral testing (mean ± SEM = 3.5
± 0.6) for 26 patients (17 amyloid-negative and 9 amyloid-
positive). These patients matched the overall group of patients
in age, education, MMSE and gender. A Shapiro test revealed
that the values for age, education and MMSE were not normally
distributed, thus nonparametric tests were employed (age:
Wilcoxon W = 510, p > 0.6; education: Wilcoxon W =
473.5, p > 0.9; MMSE: Wilcoxon W = 486.5, p > 0.9;
gender: X2 < 0.001, p > 0.9; disease duration: Wilcoxon
W = 507.5, p > 0.2). Reasons for exclusion from the MRI
study included issues related to health and safety (e.g., metallic
implants, shrapnel, claustrophobia), intercurrent medical illness,
and lack of interest in participating in an imaging study. MRI
volumes were acquired using an MPRAGE sequence from a
SIEMENS 3.0T Trio scanner with an 8-channel head coil and the
following acquisition parameters: repetition time = 1620msec;
echo time= 3.87msec; slice thickness= 1.0mm; flip angle= 15◦;
matrix = 192 × 256, and in-plane resolution = 1.0 ×
1.0mm. Whole-brain MRI volumes were preprocessed using
PipeDream (https://sourceforge.net/projects/neuropipedream/)
and Advanced Normalization Tools (http://www.picsl.upenn.
edu/ANTS/) using a procedure described previously (Avants
et al., 2008; Klein et al., 2010). Resulting images were warped into
TABLE 2 | Neuropathological information and Alzheimer’s disease
neuropathological diagnosis criteria on 5 patients for whom autopsy
examination was available.
Patient PMI Brian
volume
Clinical
phenotype
Probability-
AD-pathology
Study-specific
group
N1 7 1079 DLB Low Amyloid-negative
N2 23.5 1220 PDD Low Amyloid-negative
N3 10 1390 PDD None Amyloid-negative
N4 14 1322 PDD Intermediate Amyloid-positive
N5 9.5 1258 PDD High Amyloid-positive
MNI space, smoothed using a 4mm full-width half-maximum
Gaussian kernel, and downsampled to 2mm resolution.
Permutation-based imaging analyses were performed with
threshold-free cluster enhancement (TFCE; Smith and Nichols,
2009) using the randomize tool in FSL (http://fsl.fmrib.ox.ac.
uk/fsl/fslwiki). GM density was compared in patients relative to
healthy seniors who were part of an independent group of 32
healthy seniors with imaging who matched the patient group
for education (Wilcoxon W = 374, p > 0.1), age (Wilcoxon
W = 330.5, p > 0.1) and gender (X2 = 0.19, p > 0.7).
Considering that the main purpose of the imaging analysis is to
regress the behavioral performance against GM density in the
patients group and that the scans of healthy seniors have been
employed only to determine the atrophy mask, the use of an
independent group of healthy seniors does not compromise the
quality of the analysis (for a similar strategy see e.g., Grossman
et al., 2004; Henry et al., 2008; Healey et al., 2015; Ash et al., 2016).
A t-test analysis was run with 10,000 permutations and restricted
to voxels containing GM using an explicit mask generated from
the average GM density map of all participants. We report
clusters that survived a threshold of p < 0.05 with family-wise
error (FWE) correction for multiple comparisons and contained
a minimum of 100 adjacent voxels.
To relate behavioral performance to regions of significant
GM disease, we used the randomize tool of FSL with TFCE
technique as described above. We run a regression analysis
between patients’ performance in the task and the GM density in
regions of the brain showing decreasing GM density with respect
to the pool of healthy seniors in order to focus our analysis to
regions probably affected by the disease state. The regression
model included the Aβ status (positive or negative) as a variable
of interest. Permutations were run exhaustively up to amaximum
of 10,000. We report clusters surviving a height threshold of
p < 0.005 (uncorrected) and a minimum of 20 adjacent
voxels.
RESULTS
Behavioral Results
A regression model was built to test if the performance of the
group of LBD patients (N = 37) differed from the performance
of the healthy seniors (N = 30). The model also included age
as covariate. The results showed a significant main effect of the
Experimental condition (Survey or Coordination: t = −3.57,
p < 0.001, Cohen’s d = −0.6), a main effect of Group (healthy
seniors or patients: t = −2.12, p < 0.05, Cohen’s d = −0.4),
and an interaction between the two variables (Experimental
condition∗Group: t = 2.77, p < 0.01, Cohen’s d = 0.5). Age
also reached a significant threshold (t = −3.83, p < 0.001,
Cohen’s d = −0.7). However, a follow up analysis that included
Experimental condition∗Age in the model revealed no significant
effect of the interaction between the two variables (t = 0.548;
p > 0.5, Cohen’s d = 0.1). These findings, summarized in
Figure 1A, showed that LBD patients are significantly impaired
in their social decision-making ability compared with healthy
seniors.
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FIGURE 1 | Behavioral results. The coordination index represent the frequency with which a specific answer has been provided by the pool of healthy seniors. The
error bars represent the standard deviation of the mean while the square brackets and the stars display the significant effect of interaction. (A) Comparison between
the performance of healthy seniors and the performance of the global group of patients. (B) Comparison between the performance of amyloid-positive patients and
the performance of amyloid-negative patients.
We have also investigated the influence of being part of
different ethnical groups on the behavioral performance in our
task. The majority of our group of participants was composed by
Caucasian-white American people (58 participants out of 67). In
the group of healthy seniors 7 participants were Black-Americans
and 1 had mixed heritage. In the group of patients only
1 participant was Black-American. An exploratory regression
model in which we added ethnicity as a regressor, but excluded
the single participant with mixed heritage, showed that this
variable did not explain a significant amount of variance (t =
1.282; p > 0.2, Cohen’s d = 0.2). A follow up analysis
restricted to healthy seniors, among whom there was the largest
subgroup of Black-Americans, revealed no effect of ethnicity on
the performance in the task [ethnicity: t = −0.888; p > 3,
Cohen’s d = −0.2; ethnicity∗experimental condition (survey—
coordination): t = 1.620; p > 0.1, Cohen’s d = 0.4].
CSF analysis and autopsy exam identified that 32% of LBD
patients had evidence of Aβ, consistent with prior reports (Hurtig
et al., 2000; Irwin et al., 2013; McMillan and Wolk, 2016; see
Table 1 for further details). Another regression model was built
to test the differences between the amyloid-positive (N = 12)
and amyloid-negative (N = 25) groups of patients. The two
groups of patients differ in their average level of education and
MMSE score, thus both scores were included as covariates in
the model as well as disease duration. The results revealed no
main effect of the experimental condition (t = −0.80, p > 0.4,
Cohen’s d = −0.2) or patient group (t = −1.54, p > 0.1,
Cohen’s d = −0.4), but a significant interaction effect between
the experimental condition and the patient group was found
(t = 2.01, p < 0.05, Cohen’s d = 0.5). None of the covariates
explained a significant amount of variance (MMSE: t = 1.44,
p > 0.1, Cohen’s d = 0.4; disease duration t = −0.74, p > 0.4,
Cohen’s d = −0.2; level of education: t = −0.61, p > 0.5,
Cohen’s d = −0.1). As shown in Figure 1B, amyloid-negative
patients tended to choose uncommon referents in the survey
condition but then shifted to more common referents in the
coordination condition. By comparison, amyloid-positive patients
tended to choose more common referents in the survey condition
but did not coordinate in the coordination condition and tended
to produce less common referents.
To test whether the presence of dementia could explain
coordination difficulty, we also examined performance in
patients diagnosed clinically with dementia (PDD or DLB,
N = 14) compared with patients without dementia (PD or
PD-MCI patients; N = 23). Although the sample is small,
a regression analysis showed no significant main effects or
interaction effect [phenotype (Clinically demented patients or
non-demented patients): t = 0.33, p > 0.7, Cohen’s d = 0.1;
Experimental variable (Survey or Coordination): t = 0.93,
p > 0.3, Cohen’s d = 0.2; interaction: t=−1.51, p > 0.2, Cohen’s
d =−0.4].
Imaging Results
We first compared GM density in patients versus the group
of healthy seniors. The results revealed significant atrophy
in patients bilaterally in lateral prefrontal cortex, medial
orbitofrontal cortex, middle temporal regions, and insular cortex,
as well as significant atrophy in the right fusiform gyrus. Atrophy
coordinates are summarized in Table 3. A regression analysis
with Aβ status (positive or negative) and behavioral performance
(Survey or Coordination condition) as regressors of interest
revealed a significant interaction between the two regressors
in the medial orbitofrontal cortex (mOFC; BA 11). In other
words (see Figure 2), difficulty with social decision-making in
the amyloid-positive group was associated with gray matter
atrophy in mOFC. This region as been previously linked to social
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TABLE 3 | Regions with reduced gray matter density in the patients’ cohort respect to the group of healthy seniors (A), Results of the regression analysis
showing a significant interaction between Aβ status (positive or negative) and behavioral performance (Survey or Coordination condition) (B).
Patients < healthy seniors L/R No voxels t-value (max) p-value MNI Coordinates
x y z
(A) REDUCED GM (BA)
Middle tempral gyrus, superior temporal gyrus (21–22) and insular cortex L 6097 5.21 <0.01 −64 −30 2
Anterior cingulate cortex and medial prefrontal cortex (10–11) L/R 1326 5.03 <0.05 10 48 6
Fusiform gyrus R 425 4.03 <0.05 30 −8 −38
Middle temporal gyrus (21) R 245 4.14 <0.05 68 −32 −12
Superior temporal gyrus (22) R 175 4.01 <0.05 68 −32 18
Insular cortex L 149 4.83 <0.05 44 2 −2
(B) RESULTS OF THE REGRESSION ANALYSIS IN THE LBD COHORT (BA)
Medial orbitofrontal cortex (11) L/R 21 3.73 <0.005 −6 36 −12
BA, Brodmann area; MNI, Montreal Neurological Institute.
FIGURE 2 | Significant gray matter atrophy in the global group of patients (this includes areas colored both in blue and in red) and regions (in red only)
that showed a significant interaction between Experimental conditions (Survey and Coordination conditions) and the patients’ amyloid status
(amyloid-positive and amyloid-negative patients).
decision-making and, in particular to the neural underpinnings
of task employed we employed here (Murray et al., 2007; Wallis,
2007; McMillan et al., 2012). This region also shows increased
burden of Aβ in autopsy studies of LBD (McMillan and Wolk,
2016).
DISCUSSION
In the present study we examined patients with a LBD to
investigate the extent to which concomitant amyloid burden
worsens the decision-making profile of these patients. We
employed a task previously studied in neurodegenerative disease
that depends on a decision-making network in prefrontal
cortex. The results revealed that amyloid-positive patients have
reduced decision-making abilities relative to amyloid-negative
patients. The imaging analysis related significant decision-
making difficulty in amyloid-positive patients to atrophy in
medial orbitofrontal cortex, a region that has been previously
implicated in decision-making. In particular, previous work
has implicated the same region in perspective-taking during
social interactions (Mehta et al., 1994; McMillan et al., 2012;
Healey et al., 2015). McMillan et al. (2012), for example, showed
that poor performance in the same social-coordination task
that was employed here, related with cortical thinning in the
mOFC in bvFTD patients. In mOFC has been implicated as
well in processes like encoding stimulus-outcome contingencies,
assessing potential risk and reward, and performing tasks
involving reversal learning or response inhibition (Murray et al.,
2007; Viskontas et al., 2007; Wallis, 2007).
Many studies have documented the accumulation of amyloid
pathology in a large percentage of patients with LBD (Hurtig
et al., 2000; Siderowf et al., 2010; Irwin et al., 2012; Kotzbauer
et al., 2012). This includes patients with the clinical diagnosis
of DLB and PDD (Irwin et al., 2012; Kotzbauer et al., 2012),
as well as patients with PD-MCI and even in patients with
early, untreated PD who have no apparent cognitive impairment
(Alves et al., 2010). The consequences of accumulating amyloid
for cognitive impairment in LBD have been unclear. While
some studies have reported an association between cognitive
impairment and amyloid accumulation in LBD (Alves et al.,
2010; Siderowf et al., 2010; Petrou et al., 2012), there are several
potential sources of confound. On the one hand, some of the
controversy surrounding the extent of cognitive impairment in
LBD may be due in part to due to the neuropsychological tests
that have been used as markers of cognitive impairment, since
many studies have focused on non-specific cognitive measures
such as MoCA, MMSE, or the Mattis Dementia Rating Scale. For
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example, these inconsistently emphasize a variety of cognitive
skills that may or may not be sensitive to the cognitive deficits
in LBD. It is for this reason that we decided to examine a
specific measure of decision-making where we could clearly
determine whether a patient has a deficit. This measure has
minimal resource demands since it requires an untimed, single
word response to a simple question.
Another potential confound has to do with the manner in
which amyloid accumulation is ascertained. Previous studies
have used either amyloid PET or CSF Aβ1−42 as a proxy
for brain amyloid. While each appears to be a valid measure
of amyloid, there has been some concern about validating
the relationship between amyloid and cognitive dysfunction,
particularly given the inconsistent presence of amyloid at
autopsy in LBD. In this study, amyloid status was assessed
in each individual. We used CSF level of amyloid as a
surrogate reflecting amyloid burden in the brain, in addition
to direct post-mortem evaluation in a subset of cases. We
found that CNS amyloidosis is present in 32% of patients
participating in this study, and CSF amyloid levels were
reduced in all clinical subgroups of LBD patients. The
results of the present study cannot be easily attributed to a
general decrement in cognitive performance in the amyloid-
positive group because amyloid-positive patients showed worse
performance than amyloid-negative patients even after including
MMSE, level of education, and disease duration in the regression
model.
Several shortcomings should be taken into consideration in
evaluating the results of the present work. Although we used
patients from a deeply endophenotyped dataset that requires
critical collection of multiple forms of data, the number of
patients is relatively small. Thus, the inferences we derive
from the present analysis must be verified in future studies
employing a larger cohort. Additional studies with different
behavioral protocols are needed to evaluate the extent to which
amyloid burden contributes to decision-making as well as to
other cognitive domains that depend on other neural networks.
While amyloid burden is widely distributed throughout the gray
matter in these patients, recent work has associated amyloid
burden in specific brain regions with worse cognitive functioning
that depends in part on the target regions. For example, early
evidence of amyloid in de novo PD has been associated with
impaired verbal fluency and disease in regions similar to those
observed in the current study (e.g., mOFC) (McMillan and
Wolk, 2016). We cannot entirely rule out that possible executive
limitations, such as the ones tested by a verbal fluency test, had
an impact on the performance in our task. However, it can
be argued that decision-making processes are partially rooted
in executive resources and than the two cannot be entirely
disentangled. More precisely McMillan et al. (2012) have found
that, in a cohort of bvFTD patients, performance in the very
same task employed here correlated with the scores in the
Visual-Verbal test (Feldman and Drawgow, 1960), which test
mental flexibility. In addition to that, it is possible that social
coordination is partially based on probability-estimation, which
is also heavily dependent upon executive resources such as
mental flexibility and working memory (see e.g., Brand et al.,
2005, 2007; Del Missier et al., 2010). However, future studies
must address questions about the specificity of our task and
his redundancy in respect with other exiting tasks like verbal
fluency or MMSE as well as the relevance of specific facets of the
executive functions for the execution of the social-coordination
task. At the moment we would just like to point out that
a task that test a multidimensional process such as social-
coordination can still be of clinical interest because it might
provide a more “realistic” testing ground in respect to standard
neuropsychological tests.
Another possible shortcoming of the present work is the
heterogeneity of the clinical cohort. Future works should
investigate the impact of the different clinical phenotypes
within the LBD spectrum to the interaction between amyloid
burden and decision-making abilities. Cognitive deficits can vary
drastically among phenotypes but our claims are restricted to
a single decision-making test that has been administered to all
the participants and a regression analysis showed no significant
interaction between clinical phenotype and the performance in
the task. In addition to that, significant amyloid burden can be
found in LBD patients across the boarders of clinical phenotypes
(see e.g., Irwin et al., 2013; McMillan and Wolk, 2016).
We acknowledge also that there was a great variability in the
interval between behavioral testing and the collection of CSF as
well as in the interval between behavioral testing and death in
our sample (see Table 1). Although we cannot completely rule
out that the delay between behavioral testing and both CSF and
neuropathological examination could be a confounding factor,
previous studies have shown that, at least in Alzheimer’s disease,
the level of beta-amyloid in the brain reaches a plato early on and
stays almost stable over the course of disease progression (see e.g.,
Engler et al., 2006; Sperling et al., 2011). Therefore, the estimation
of beta-amyloid level via CSF or neuropatholagical examination
can be considered as a stable value.
It must be also noticed that the age of the participants explains
a significant amount of variance in our first regression model.
However, a follow up analysis that included the interaction
between the experimental condition and age in the model
revealed that this term did not explain a significant amount
of variance. Moreover, the main focus of our study was the
comparison within the patients group and in this scenario the
age of the amyloid-positive and the age of the amyloid-negative
patients were tightly matched.
Another possible caveat is that amyloid co-occurs with tau
in the form of neurofibrillary tangles in these patients, and we
cannot rule out the possibility that tau burden also contributes to
decision-making difficulty in these patients. With these caveats
in mind, we conclude that the present work provides preliminary
evidence that links impaired decision-making to Aβ burden that
reflects the accumulation of amyloid in the prefrontal cortex of
patients with a LBD.
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